Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.78 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 3/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066733 | 0.93 | NR3C2 (0.68) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL2437620 | 0.90 | NR3C2 (0.78) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL2443971 | 0.90 | NR3C2 (0.75) | NR3C2PDE7AGPR27AVPR2PDE4A | |
| SCHEMBL1380377 | 0.89 | NR3C2 (0.67) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL1381640 | 0.88 | NR3C2 (0.61) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL1380260 | 0.88 | NR3C2 (0.61) | NR3C2PDE7ASMN1; SMN2 | |
| SCHEMBL1381714 | 0.88 | NR3C2 (1.00) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL1384601 | 0.88 | NR3C2 (0.61) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL29571805 | 0.88 | NR3C2 (1.00) | NR3C2PDE7AMAOAMAOBGPR27 | |
| SCHEMBL2439013 | 0.87 | NR3C2 (0.59) | NR3C2MAOAMAOBGPR27AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | claimed |
| JP-4703649-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11331308-B2 | Combination containing sGC activators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210121461-A1 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | Bayer Pharma AG (DE) | 2021-04-29 | — | — | US | disclosed |
| US-10918639-B2 | Combination containing SGC stimulators and mineralocorticoid receptor antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-16 | — | — | US | disclosed |
| US-20190262363-A1 | ANTAGONIST OF MINERALOCORTICOID RECEPTOR FOR THE TREATMENT OF OSTEOARTHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190262340-A1 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | BAYER PHARAMA AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| WO-2018069126-A1 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018069148-A1 | COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | NR3C2 119/4885PDE7A 258/4885MAOA 686/4885 |
| US-20190262363-A1 | ANTAGONIST OF MINERALOCORTICOID RECEPTOR FOR THE TREATMENT OF OSTEOARTHRITIS | MC2R, NR3C2, ADIPOR1 | NR3C2 2/4885PDE7A 2800/4885MAOA 2523/4885 |
| US-10918639-B2 | Combination containing SGC stimulators and mineralocorticoid receptor antagonists | NR3C2, GUCY1A1, GUCY1A2 | NR3C2 1/4885PDE7A 185/4885MAOA 3488/4885 |
| US-11331308-B2 | Combination containing sGC activators and mineralocorticoid receptor antagonists | NR3C2, PTGIR, MC2R | NR3C2 1/4885PDE7A 202/4885MAOA 3182/4885 |
| US-11684621-B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | NR3C2, GUCY1A1, GUCY1A2 | NR3C2 1/4885PDE7A 185/4885MAOA 3488/4885 |
| US-20210121461-A1 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, GUCY1A1, GUCY1A2 | NR3C2 1/4885PDE7A 185/4885MAOA 3488/4885 |
| US-20190262340-A1 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, GUCY1A1, GUCY1A2 | NR3C2 1/4885PDE7A 185/4885MAOA 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.